o-(Trifluormethylthio)benzolsulfamid | 37526-60-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: o-(Trifluormethylthio)benzolsulfamid
• 英文别名: 2-(Trifluoromethylsulfanyl)benzenesulfonamide
• CAS: 37526-60-6
• 化学式: C₇H₆F₃NO₂S₂
• 分子量: 257.257
• InChiKey: VSJOBSSCBPOXHS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  93.8
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• [EN] CONSTRAINED TRICYCLIC SULFONAMIDES<br/>[FR] SULFAMIDES TRICYCLIQUES CONTRAINTS
  申请人：ICAHN SCHOOL MED MOUNT SINAI

  公开号：WO2015138496A1

  公开（公告）日：2015-09-17

  Tricyclic chemical modulators of protein phosphatase 2A are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne. The compounds are of the following phenothiazine and dibenzoazepine compounds and similar genera:

  三环化学调节剂蛋白磷酸酶2A被披露。这些化合物可用于治疗癌症、年龄相关的蛋白质毒性、压力诱发的抑郁症、炎症和痤疮。这些化合物属于以下苯噻嗪和二苯并噻吩化合物及类似的类属：
• [EN] SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT<br/>[FR] INHIBITEURS À PETITES MOLÉCULES DE MUTANT DE KRAS G12D
  申请人：MERCK SHARP & DOHME

  公开号：WO2022221739A1

  公开（公告）日：2022-10-20

  Compounds or their pharmaceutically acceptable salts can inhibit the G12D mutant of Kirsten rat sarcoma (KRAS) protein and are expected to have utility as therapeutic agents, for example, for treating cancer. The disclosure also provides pharmaceutical compositions which comprise compounds disclosed herein or pharmaceutically acceptable salts thereof. The disclosure also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of cancer and for preparing pharmaceuticals for this purpose.

  化合物或其药学上可接受的盐可以抑制Kirsten大鼠肉瘤（KRAS）蛋白的G12D突变，并预计具有治疗剂的效用，例如，用于治疗癌症。本公开还提供了包含此处披露的化合物或其药学上可接受的盐的制药组合物。本公开还涉及使用该化合物或其药学上可接受的盐在癌症治疗和预防以及为此目的制备制药的方法。
• CONSTRAINED TRICYCLIC SULFONAMIDES
  申请人：Icahn School of Medicine at Mount Sinai

  公开号：EP3116857A1

  公开（公告）日：2017-01-18